|
Toggle Summary
May 3, 2018
|
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter
|
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
|
|
Toggle Summary
April 26, 2018
|
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
Management to host conference call WALTHAM, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
|
|
Toggle Summary
April 9, 2018
|
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Multi-center trial to enroll approximately 324 patients at approximately 40 clinical sites in U.S. and Europe WALTHAM, Mass. , April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat
|
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
|
|
Toggle Summary
March 15, 2018
|
Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
WALTHAM, Mass. , March 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will host a Key Opinion Leader (KOL) meeting on the topic of
|
Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
|
|
Toggle Summary
March 12, 2018
|
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
|
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
|
|
Toggle Summary
March 5, 2018
|
Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
Management to host conference call WALTHAM, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
|
|
Toggle Summary
February 5, 2018
|
Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
WALTHAM, Mass. , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Dr. Rémy Luthringer has been appointed as Executive Chairman of
|
Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
|
|
Toggle Summary
December 21, 2017
|
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
WALTHAM, Mass. , Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in a Phase 2b
|
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder
|
|
Toggle Summary
December 19, 2017
|
Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
WALTHAM, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the screening of the first patient in the pivotal Phase 3 clinical trial of MIN-101 (Study MIN-101C07) as monotherapy for negative symptoms in patients diagnosed with schizophrenia.
|
Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
|
|
Toggle Summary
December 11, 2017
|
Minerva Neurosciences Names Richard Russell President
WALTHAM, Mass. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Rick Russell as President. Dr.
|
Minerva Neurosciences Names Richard Russell President
|
